Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ) has issued an announcement.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced the fulfilment of certain pre-conditions related to its proposed merger with Sunshine Lake Pharma Co., Ltd. The merger, structured as a merger by absorption, has met Pre-Conditions (1) and (3), involving necessary governmental approvals and shareholder approval. However, Pre-Condition (2), which pertains to the listing and vetting process with the Stock Exchange and SFC, is still pending. The completion of this merger is expected to impact the company’s operations and market positioning, with further announcements to be made as developments occur.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a pharmaceutical company based in the People’s Republic of China, focusing on the development and production of pharmaceutical products. It operates in the healthcare industry, with a market focus on providing medical solutions and products.
Average Trading Volume: 7,458,003
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$11.49B
For a thorough assessment of 1558 stock, go to TipRanks’ Stock Analysis page.